Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors

Please use this identifier to cite or link to this item: http://10.1.7.192:80/jspui/handle/123456789/5330

Full metadata record

DC Field	Value	Language
dc.contributor.author	Patel, Bhumika	-
dc.date.accessioned	2015-01-24T05:17:43Z	-
dc.date.available	2015-01-24T05:17:43Z	-
dc.date.issued	2014	-
dc.identifier.uri	http://hdl.handle.net/123456789/5330	-
dc.description	European Journal of Medicinal Chemistry 74 (2014) 574e605	en_US
dc.description.abstract	Dipeptidyl peptidase-4 (DPP-4) is one of the widely explored novel targets for Type 2 diabetes mellitus (T2DM) currently. Research has been focused on the strategy to preserve the endogenous glucagon like peptide (GLP)-1 activity by inhibiting the DPP-4 action. The DPP-4 inhibitors are weight neutral, well tolerated and give better glycaemic control over a longer duration of time compared to existing conventional therapies. The journey of DPP-4 inhibitors in the market started from the launch of sitagliptin in 2006 to latest drug teneligliptin in 2012. This review is mainly focusing on the recent medicinal aspects and advancements in the designing of DPP-4 inhibitors with the therapeutic potential of DPP-4 as a target to convey more clarity in the diffused data. Peptidomimetics	en_US
dc.publisher	Elsevier	en_US
dc.relation.ispartofseries	IPFP0138;	-
dc.subject	Dipeptidyl peptidase-4	en_US
dc.subject	Glucagon like peptide (GLP)-1	en_US
dc.subject	Non-peptidomimetics	en_US
dc.subject	Diabetes	en_US
dc.title	Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors	en_US
dc.type	Faculty Papers	en_US
Appears in Collections:	Faculty Papers

Files in This Item:

File	Description	Size	Format
IPFP0138.pdf	IPFP0138	4.45 MB	Adobe PDF	View/Open

IR @ Nirma University